# Regulation of Bone Formation in Renal Osteodystrophy

> **NCT00560300** · PHASE2 · COMPLETED · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 61 (actual)

## Conditions studied

- Secondary Hyperparathyroidism
- Renal Osteodystrophy

## Interventions

- **DRUG:** 1 alpha D2
- **DRUG:** 1,25 dihydroxy vitamin D3
- **DRUG:** Sevelamer HCl
- **DRUG:** Calcium Carbonate

## Key facts

- **NCT ID:** NCT00560300
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-11
- **Primary completion:** —
- **Final completion:** 2006-11
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2010-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00560300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00560300, "Regulation of Bone Formation in Renal Osteodystrophy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00560300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*